亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study

医学 免疫抑制 无容量 内科学 临床终点 人口 肾癌 临床试验 肿瘤科 肌酐 癌症 免疫疗法 环境卫生
作者
Robert P. Carroll,Michael Boyer,Val Gebski,Bronwyn Hockley,Julie Johnston,Svjetlana Kireta,Hsiang Tan,Anne E. Taylor,Kate Wyburn,John Zalcberg
出处
期刊:Lancet Oncology [Elsevier]
卷期号:23 (8): 1078-1086 被引量:38
标识
DOI:10.1016/s1470-2045(22)00368-0
摘要

Background Most kidney transplant recipients with cancer stop or reduce immunosuppressive therapy before starting treatment with an immune checkpoint inhibitor, and approximately 40% of such patients will develop allograft rejection. Isolated immunosuppression reduction might be associated with organ rejection. Whether immunosuppression manipulation, immune checkpoint inhibition, or both, induce organ rejection is difficult to ascertain. The aim of this study was to examine the risk of allograft rejection with immune checkpoint inhibitor exposure when baseline immunosuppression was left unchanged. Methods We conducted a multicentre, single-arm, phase 1 study in three hospitals in Australia. Kidney transplant recipients aged 18 years or older with incurable, locally advanced cancer or defined metastatic solid tumours were eligible if they had a creatinine concentration of less than 180 mmol/L, no or low concentrations of donor-specific HLA antibodies, and an Eastern Cooperative Oncology Group status of 0–2. Patients received standard doses of nivolumab (3 mg/kg intravenously every 14 days for five cycles, then 480 mg every 28 days for up to 2 years). The primary endpoint was the proportion of patients with irretrievable allograft rejection and no evidence of tumour response. Primary outcome analyses and safety analyses were done in the modified intention-to-treat population. This trial is registered with the Australian and New Zealand Clinical Trials Register, ANZCTR12617000741381, and is completed. Findings Between May 31, 2017, and Aug 6, 2021, 22 kidney transplant recipients with various solid tumours were screened and enrolled, four of whom chose not to proceed in the study and one of whom had unexpected disease progression. 17 patients (six [35%] women and 11 [65%] men; median age 67 years [IQR 59–71]) were allocated treatment with nivolumab and were included in the analyses. The trial was then stopped due to ongoing difficulties with running clinical trials during COVID-19 health restrictions. Patients were treated with a median of three infusions (IQR 2–10) and median follow-up was 28 months (IQR 16–34). No patients had irretrievable allograft rejection without evidence of tumour response. There were no treatment-related deaths or treatment-related serious adverse events. The most common grade 3 or grade 4 adverse events were decreased lymphocyte count in four (24%) patients, fever or infection in four (24%) patients, decreased haemoglobin in three (18%) patients, and increased creatinine in three (18%) patients. Interpretation Maintaining baseline immunosuppression before treatment with an immune checkpoint inhibitor in kidney transplant recipients might not affect expected efficacy and might reduce the risk of allograft rejection mediated by immune checkpoint inhibitors. Funding Bristol Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎应助科研通管家采纳,获得50
28秒前
1分钟前
zjz发布了新的文献求助10
1分钟前
1分钟前
1分钟前
zjz完成签到,获得积分10
1分钟前
栗子发布了新的文献求助10
1分钟前
龙虾发票发布了新的文献求助10
1分钟前
bkagyin应助栗子采纳,获得10
1分钟前
庾无敌完成签到 ,获得积分10
2分钟前
Perry完成签到,获得积分10
3分钟前
大个应助cc采纳,获得10
4分钟前
柯语雪完成签到 ,获得积分10
4分钟前
4分钟前
cc发布了新的文献求助10
4分钟前
神经蛙完成签到,获得积分10
4分钟前
甜美的问蕊完成签到 ,获得积分10
6分钟前
新世界的蜗牛完成签到,获得积分10
6分钟前
7分钟前
7分钟前
祖之微笑发布了新的文献求助200
7分钟前
FSYHantis完成签到,获得积分10
8分钟前
宋丽薇完成签到,获得积分10
8分钟前
上官若男应助cc采纳,获得10
9分钟前
缪静柏发布了新的文献求助30
10分钟前
祖之微笑完成签到,获得积分10
10分钟前
10分钟前
六月初八夜完成签到,获得积分10
10分钟前
cc发布了新的文献求助10
10分钟前
10分钟前
李健的粉丝团团长应助1577采纳,获得10
10分钟前
喵喵完成签到 ,获得积分10
10分钟前
猪皮恶人发布了新的文献求助10
10分钟前
10分钟前
祖之微笑发布了新的文献求助10
10分钟前
10分钟前
1577发布了新的文献求助10
11分钟前
11分钟前
缪静柏发布了新的文献求助10
11分钟前
1577完成签到,获得积分10
11分钟前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
Diamonds: Properties, Synthesis and Applications 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099758
求助须知:如何正确求助?哪些是违规求助? 2751215
关于积分的说明 7612024
捐赠科研通 2403006
什么是DOI,文献DOI怎么找? 1275089
科研通“疑难数据库(出版商)”最低求助积分说明 616238
版权声明 599033